Edwin Liu1, Hye-Seung Lee, Carin A Aronsson, William A Hagopian, Sibylle Koletzko, Marian J Rewers, George S Eisenbarth, Polly J Bingley, Ezio Bonifacio, Ville Simell, Daniel Agardh. 1. From the Digestive Health Institute, Children's Hospital Colorado (E.L.), and the Barbara Davis Center (E.L., M.J.R., G.S.E.), University of Colorado Denver, Aurora; the Pediatrics Epidemiology Center, University of South Florida, Tampa (H.-S.L.); the Diabetes and Celiac Disease Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden (C.A.A., D.A.); Pacific Northwest Diabetes Research Institute, Seattle (W.A.H.); Dr. von Hauner Children's Hospital, Ludwig Maximilian University, Munich (S.K.), the Center for Regenerative Therapies Dresden, Technische Universitaet Dresden, Dresden (E.B.), and Forschergruppe Diabetes, Helmholz Zentrum München, Neuherberg (E.B.) - all in Germany; the School of Clinical Sciences, University of Bristol, Bristol, United Kingdom (P.J.B.); and the Department of Pediatrics, University of Turku, Turku University Hospital, Turku, Finland (V.S.).
Abstract
BACKGROUND: The presence of HLA haplotype DR3-DQ2 or DR4-DQ8 is associated with an increased risk of celiac disease. In addition, nearly all children with celiac disease have serum antibodies against tissue transglutaminase (tTG). METHODS: We studied 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8 prospectively from birth in the United States, Finland, Germany, and Sweden. The primary end point was the development of celiac disease autoimmunity, which was defined as the presence of tTG antibodies on two consecutive tests at least 3 months apart. The secondary end point was the development of celiac disease, which was defined for the purpose of this study as either a diagnosis on biopsy or persistently high levels of tTG antibodies. RESULTS: The median follow-up was 60 months (interquartile range, 46 to 77). Celiac disease autoimmunity developed in 786 children (12%). Of the 350 children who underwent biopsy, 291 had confirmed celiac disease; an additional 21 children who did not undergo biopsy had persistently high levels of tTG antibodies. The risks of celiac disease autoimmunity and celiac disease by the age of 5 years were 11% and 3%, respectively, among children with a single DR3-DQ2 haplotype, and 26% and 11%, respectively, among those with two copies (DR3-DQ2 homozygosity). In the adjusted model, the hazard ratios for celiac disease autoimmunity were 2.09 (95% confidence interval [CI], 1.70 to 2.56) among heterozygotes and 5.70 (95% CI, 4.66 to 6.97) among homozygotes, as compared with children who had the lowest-risk genotypes (DR4-DQ8 heterozygotes or homozygotes). Residence in Sweden was also independently associated with an increased risk of celiac disease autoimmunity (hazard ratio, 1.90; 95% CI, 1.61 to 2.25). CONCLUSIONS: Children with the HLA haplotype DR3-DQ2, especially homozygotes, were found to be at high risk for celiac disease autoimmunity and celiac disease early in childhood. The higher risk in Sweden than in other countries highlights the importance of studying environmental factors associated with celiac disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others.).
BACKGROUND: The presence of HLA haplotype DR3-DQ2 or DR4-DQ8 is associated with an increased risk of celiac disease. In addition, nearly all children with celiac disease have serum antibodies against tissue transglutaminase (tTG). METHODS: We studied 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8 prospectively from birth in the United States, Finland, Germany, and Sweden. The primary end point was the development of celiac disease autoimmunity, which was defined as the presence of tTG antibodies on two consecutive tests at least 3 months apart. The secondary end point was the development of celiac disease, which was defined for the purpose of this study as either a diagnosis on biopsy or persistently high levels of tTG antibodies. RESULTS: The median follow-up was 60 months (interquartile range, 46 to 77). Celiac disease autoimmunity developed in 786 children (12%). Of the 350 children who underwent biopsy, 291 had confirmed celiac disease; an additional 21 children who did not undergo biopsy had persistently high levels of tTG antibodies. The risks of celiac disease autoimmunity and celiac disease by the age of 5 years were 11% and 3%, respectively, among children with a single DR3-DQ2 haplotype, and 26% and 11%, respectively, among those with two copies (DR3-DQ2 homozygosity). In the adjusted model, the hazard ratios for celiac disease autoimmunity were 2.09 (95% confidence interval [CI], 1.70 to 2.56) among heterozygotes and 5.70 (95% CI, 4.66 to 6.97) among homozygotes, as compared with children who had the lowest-risk genotypes (DR4-DQ8 heterozygotes or homozygotes). Residence in Sweden was also independently associated with an increased risk of celiac disease autoimmunity (hazard ratio, 1.90; 95% CI, 1.61 to 2.25). CONCLUSIONS: Children with the HLA haplotype DR3-DQ2, especially homozygotes, were found to be at high risk for celiac disease autoimmunity and celiac disease early in childhood. The higher risk in Sweden than in other countries highlights the importance of studying environmental factors associated with celiac disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others.).
Authors: S Husby; S Koletzko; I R Korponay-Szabó; M L Mearin; A Phillips; R Shamir; R Troncone; K Giersiepen; D Branski; C Catassi; M Lelgeman; M Mäki; C Ribes-Koninckx; A Ventura; K P Zimmer Journal: J Pediatr Gastroenterol Nutr Date: 2012-01 Impact factor: 2.839
Authors: Lars C Stene; Margo C Honeyman; Edward J Hoffenberg; Joel E Haas; Ronald J Sokol; Lisa Emery; Iman Taki; Jill M Norris; Henry A Erlich; George S Eisenbarth; Marian Rewers Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: E Bazzigaluppi; V Lampasona; G Barera; A Venerando; C Bianchi; G Chiumello; E Bonifacio; E Bosi Journal: J Autoimmun Date: 1999-02 Impact factor: 7.094
Authors: Edward J Hoffenberg; Todd MacKenzie; Katherine J Barriga; George S Eisenbarth; Fei Bao; Joel E Haas; Henry Erlich; T l Bugawan Tl; Ronald J Sokol; Iman Taki; Jill M Norris; Marian Rewers Journal: J Pediatr Date: 2003-09 Impact factor: 4.406
Authors: Marcella Li; Liping Yu; Claudio Tiberti; Margherita Bonamico; Iman Taki; Dongmei Miao; Joseph A Murray; Marian J Rewers; Edward J Hoffenberg; Daniel Agardh; Patricia Mueller; Martin Stern; Ezio Bonifacio; Edwin Liu Journal: Am J Gastroenterol Date: 2009-01 Impact factor: 10.864
Authors: William A Hagopian; Henry Erlich; Ake Lernmark; Marian Rewers; Anette G Ziegler; Olli Simell; Beena Akolkar; Robert Vogt; Alan Blair; Jorma Ilonen; Jeffrey Krischer; JinXiong She Journal: Pediatr Diabetes Date: 2011-05-12 Impact factor: 3.409
Authors: Rok Seon Choung; Ivo C Ditah; Ashley M Nadeau; Alberto Rubio-Tapia; Eric V Marietta; Tricia L Brantner; Michael J Camilleri; S Vincent Rajkumar; Ola Landgren; James E Everhart; Joseph A Murray Journal: Am J Gastroenterol Date: 2015-02-10 Impact factor: 10.864
Authors: Edwin Liu; Fran Dong; Anna E Barón; Iman Taki; Jill M Norris; Brigitte I Frohnert; Edward J Hoffenberg; Marian Rewers Journal: Gastroenterology Date: 2017-02-07 Impact factor: 22.682
Authors: Rok Seon Choung; Shahryar Khaleghi; Amanda K Cartee; Eric V Marietta; Joseph J Larson; Katherine S King; Otto Savolainen; Alastair B Ross; S Vincent Rajkumar; Michael J Camilleri; Alberto Rubio-Tapia; Joseph A Murray Journal: Gastroenterology Date: 2019-09-24 Impact factor: 22.682
Authors: Benjamin Lebwohl; Joseph A Murray; Elena F Verdú; Sheila E Crowe; Melinda Dennis; Alessio Fasano; Peter H R Green; Stefano Guandalini; Chaitan Khosla Journal: Am J Gastroenterol Date: 2015-08-11 Impact factor: 10.864